Germline variants within the transcription factor RUNX1 are associated with familial platelet disorder and acute leukemia in over 40% of carriers. At present, the somatic events triggering leukemic transformation appear heterogeneous and profiles of leukemia initiation across family members are poorly defined. We report a new RUNX1 family where three sisters harboring a germline nonsense RUNX1 variant, c.601C4T (p.(Arg201*)), developed acute myelomonocytic leukemia (AML) at 5 years of age. Whole-exome sequencing of tumor samples revealed all three siblings independently acquired variants within the JAK-STAT pathway, specifically targeting JAK2 and SH2B3 (a negative regulator of JAK2), while also sharing the 46/1 haplotype linked with sporadic JAK2-positive myeloproliferative neoplasms. In-depth chromosomal characterization of tumors revealed acquired copy number gains and uniparental disomy amplifying RUNX1, JAK2 and SH2B3 variants, highlighting the significance of cooperation between these disrupted pathways. One sibling, presenting with myelodysplasia at 14 years, had no evidence of clonal or subclonal JAK2 or SH2B3 variants, suggesting the latter were specifically associated with leukemic transformation in her sisters. Collectively, the clinical and molecular homogeneity across these three young siblings provides the first notable example of convergent AML evolution in a RUNX1 pedigree, with the recurrent acquisition of JAK-STAT pathway variants giving rise to high-risk AML, characterized by chemotherapy resistance and relapse. European Journal of Human Genetics (2017) 25, 1020-1024; doi:10.1038/ejhg.2017.80; published online 17 May 2017 INTRODUCTION Acquired RUNX1 variants occur in~10% of sporadic acute myelomonocytic leukemia (AML) cases and the clinico-pathologic associations within this subgroup of disease have been comprehensively defined. 1 Inherited or germline RUNX1 variants are comparatively rare and typically cluster in the highly conserved runt homology domain, predisposing to familial platelet disorder and myelodysplasia (MDS) or acute leukemia. 2 Leukemic transformation occurs in over 40% of variant carriers, coinciding with a heterogeneous profile of somatic genetic lesions, although aberrations of the second RUNX1 allele or amplification of the germline variant are frequent. 3, 4 Notably, CDC25C variants were reported as a recurrent event in a Japanese RUNX1-mutated cohort, 5 however these results were not replicated in the US and European studies, 3, 6, 7 suggesting ethnicity may influence somatic variant acquisition. Exploring this notion further, we considered whether family members may develop similar patterns of disease, due to their common genetic background. Using comprehensive clinical and genetic profiling of multiple siblings with MDS/AML, we report striking phenotypic and molecular convergence of AML within a new Hungarian RUNX1-mutated family.
INTRODUCTION
Acquired RUNX1 variants occur in~10% of sporadic acute myelomonocytic leukemia (AML) cases and the clinico-pathologic associations within this subgroup of disease have been comprehensively defined. 1 Inherited or germline RUNX1 variants are comparatively rare and typically cluster in the highly conserved runt homology domain, predisposing to familial platelet disorder and myelodysplasia (MDS) or acute leukemia. 2 Leukemic transformation occurs in over 40% of variant carriers, coinciding with a heterogeneous profile of somatic genetic lesions, although aberrations of the second RUNX1 allele or amplification of the germline variant are frequent. 3, 4 Notably, CDC25C variants were reported as a recurrent event in a Japanese RUNX1-mutated cohort, 5 however these results were not replicated in the US and European studies, 3, 6, 7 suggesting ethnicity may influence somatic variant acquisition. Exploring this notion further, we considered whether family members may develop similar patterns of disease, due to their common genetic background. Using comprehensive clinical and genetic profiling of multiple siblings with MDS/AML, we report striking phenotypic and molecular convergence of AML within a new Hungarian RUNX1-mutated family.
DESIGN AND METHODS
We used the SureSelect All Exon V5 kit (Agilent, Santa Clara, CA, USA) to perform whole-exome sequencing (WES) on bone marrow (BM) tumor DNA from siblings (II.1-II.4) and peripheral blood (PB) DNA from both healthy parents (I.1 and I.2), the latter providing a germline reference. Enriched exome libraries were sequenced to an average depth of × 96 (Supplementary Table S1 ) using the HiSeq 2000 (Illumina, San Diego, CA, USA) with additional analysis described in Supplementary Data.
An established pipeline incorporating MuTect (single-nucleotide variants, SNVs) and GATK (indels) was employed for variant calling in tumor samples. Analysis of chromosomal loss of heterozygosity, including copy number aberrations (CNAs) and acquired uniparental disomy (aUPD) is detailed in the Supplementary Data. Sequence variants and CNAs were verified using Sanger sequencing and multiplex ligation-dependent probe amplification (MRC Holland, Amsterdam, the Netherlands, SALSA X060-X2), respectively. The WES data have been deposited in the European Genome-Phenome Archive under the accession number EGAS00001001862. Deep sequencing of JAK2 exon 14 and all coding exons of SH2B3 was performed using the AmpliSeq approach on an Ion Torrent (Life Technologies, Carlsbad, CA, USA) instrument. The reference sequences used for variant annotations are listed in the Supplementary Data. Arg392Gln) )) in SH2B3, with 12q aUPD increasing its allelic burden to 67% (Figure 2a (ii)). SH2B3 (also known as LNK) is a member of the SH2B family of adaptor proteins and negatively regulates JAK2 by interacting with the phosphorylated JAK2 tyrosine residue 813 (p.Tyr813) via a conserved SH2 domain, regulating both WT and mutant JAK2 activity. 8 By analyzing the structure of murine Sh2b, we identified that SH2B3 p.Arg392 corresponds to Sh2b p.Arg555, 9 situated in the midst of a precisely conserved region spanning 15 amino acids and forming a salt bridge with the phosphopeptide binding pocket targeted by phosphorylated JAK2. SH2B3 c.1175G4A (p.(Arg392Gln)) is a unique variant, predicted to be damaging using MutationTaster (P = 1.0000, 4 d.p., http://www. mutationtaster.org) and absent from both ExAC (http://exac.broadinstitute.org) and Thousand Genome databases (http://www.internationalgenome.org/data/). We hypothesize that p.(Arg392Gln) may therefore disrupt salt bridging with the phosphopeptide binding pocket in SH2B3, consequently reducing JAK2 inhibition, as previously described with missense variants in this domain. 10 Additional somatic variants identified across the siblings included the anaphase promoting complex component, CDC27, in II. Gln147Glu) ), VAF 41.2%) in sibling II.4. These molecular lesions are infrequently observed in sporadic MDS/AML, mirroring observations within other RUNX1 pedigrees where only one to two recurrently mutated driver events are detected in tumors. 3, 6, 7, 11 Having established the spectrum of variants across the siblings, we next sought to derive the chronological sequence of chromosomal and Val617Phe)) and 12q aUPD were followed by 9q deletion (Figure 2d ). This pattern of disease evolution revealed the selective and sequential amplification of RUNX1, JAK2 and SH2B3 variants, affirming their key roles as leukemic driver lesions.
RESULTS

A nonsense
The rarity of JAK2 and SH2B3 variants in sporadic AML cases, 13 suggested these siblings may share an inherited genotype predisposing [14] [15] [16] The mother was homozygous for the 46/1 haplotype (GG) and the father was homozygous for the non-46/1 allele (CC) (Figure 3 ). Subclonal JAK2 and SH2B3 variants were excluded in sibling II.3 and maternal DNA (I.1) by deep sequencing to a depth of × 10 000, suggesting that these lesions were specifically acquired upon leukemic transformation, potentially influenced by additional, yet unknown, genetic variants. All three siblings with AML and JAK2 upregulation demonstrated an aggressive disease course, characterized by relapse and resistance to chemotherapy. Following combination chemotherapy, II.1 achieved complete remission (CR) but died 1 year later with AML relapse. II.2 failed to achieve CR and succumbed to chemotherapy-refractory disease after 8 months. Sibling II.4 received induction chemotherapy with idarubicin, cytarabine and etoposide, and underwent unrelated double cord blood stem cell transplantation (HSCT) following a delay in hematopoietic reconstitution. AML recurred after 17 months requiring a second volunteer unrelated donor HSCT and she continues in remission with full donor chimerism 30 months post transplant.
DISCUSSION
In this study, we report a novel RUNX1 pedigree with recurrence of somatic JAK-STAT pathway variants in three siblings with aggressive myelomonocytic AML. Our data suggest that inherited genetic traits may govern leukemic transformation and disease behavior by influencing somatic variant acquisition and molecular co-operation. Concurrent disruption of JAK2 and RUNX1 has been reported in sporadic AML, where JAK2 variants occur in 5-8% of core binding factor leukemia with the t(8;21)(q22;q22) RUNX1-RUNX1T1 translocation 17, 18 and in a study of 200 AML cases, solitary SH2B3 and JAK2 c.1849G4T (p.(Val617Phe)) variants both coincided with RUNX1 variants. 13 Conversely, RUNX1 variants have also been reported during leukemic transformation of JAK2-positive MPNs. 19, 20 The lack of recurrent JAK-STAT variants in a recent study of RUNX1-mutated AML 1 suggests that this co-operation is rare and likely to be governed by additional features, including haplotype. Clinically, all three siblings with somatic JAK-STAT pathway variants demonstrated an adverse disease profile, highlighting the importance of observing phenotypic patterns of disease across family members to improve investigation, management and counseling of these rare pedigrees. 
